IMV to Host Key Opinion Leader Symposium on Role of Survivin in Cancer Biology and Potential of DPX-Survivac
The event will feature presentations by key opinion leaders, including:
Sally P. Wheatley, Ph.D., Assistant Professor, School of Life Sciences, University of Nottingham;
Jeannine Villella, D.O., FACOG, FACS, Chair of Gynecologic Oncology, Department of Obstetrics and Gynecology, Lenox Hill Hospitaland NYU Winthrop Hospital; and
Oliver Dorigo, M.D, Ph.D., Associate Professor of Obstetrics and Gynecology, Stanford University Medical Center, Stanford University Medical Center.
Additionally, IMV management will provide a corporate update, including an overview of recent data from ongoing studies of DPX-Survivac, which is currently being evaluated in three Phase 2 studies in advanced ovarian cancer, relapsed/refractory diffuse large B-cell lymphoma and a basket of solid tumor indications. Topline results are expected from all three studies in 1H20.
A live webcast of the event will be available under “Events, Webcasts and Presentations” in the Investors section of IMV’s website and will be available for replay approximately two hours following the live event.
IMV Forward-Looking Statements
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements regarding the
Marc Jasmin, IMV Senior Director, Investor Relations
O: (902) 492-1819 ext : 1042
M: (514) 617-9481 E: email@example.com
Josh Rappaport, Director, Stern IR
O: (212) 362-1200
Mrs. Delphine Davan, IMV, Director of Communications
M: (514) 968-1046